Henry Galan
Concepts (529)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Growth Retardation | 51 | 2025 | 593 | 6.490 |
Why?
| | Ultrasonography, Prenatal | 38 | 2025 | 294 | 4.170 |
Why?
| | Placenta | 29 | 2022 | 784 | 2.570 |
Why?
| | Pregnancy | 112 | 2026 | 7197 | 2.520 |
Why?
| | Ultrasonography, Doppler | 19 | 2023 | 126 | 2.460 |
Why?
| | Umbilical Arteries | 12 | 2023 | 52 | 2.250 |
Why?
| | Fetofetal Transfusion | 5 | 2025 | 26 | 1.840 |
Why?
| | Gestational Age | 38 | 2026 | 988 | 1.730 |
Why?
| | Gynecology | 4 | 2022 | 179 | 1.430 |
Why?
| | Uterine Artery | 6 | 2020 | 74 | 1.410 |
Why?
| | Fetal Diseases | 9 | 2026 | 194 | 1.390 |
Why?
| | Fetus | 24 | 2023 | 804 | 1.380 |
Why?
| | Sheep | 27 | 2017 | 882 | 1.320 |
Why?
| | Laser Coagulation | 2 | 2025 | 79 | 1.300 |
Why?
| | Pregnancy Outcome | 11 | 2024 | 497 | 1.210 |
Why?
| | Meningomyelocele | 5 | 2022 | 62 | 1.200 |
Why?
| | Fetal Weight | 7 | 2022 | 53 | 1.130 |
Why?
| | Pregnancy, Twin | 4 | 2022 | 19 | 1.100 |
Why?
| | Fetoscopy | 4 | 2025 | 33 | 1.100 |
Why?
| | Obstetrics | 6 | 2022 | 176 | 1.000 |
Why?
| | Infant, Newborn | 39 | 2026 | 6437 | 1.000 |
Why?
| | Fetal Development | 3 | 2021 | 297 | 0.880 |
Why?
| | Female | 118 | 2026 | 78763 | 0.880 |
Why?
| | Infant, Small for Gestational Age | 7 | 2022 | 117 | 0.880 |
Why?
| | Inositol | 5 | 2014 | 26 | 0.800 |
Why?
| | Hernias, Diaphragmatic, Congenital | 5 | 2025 | 221 | 0.800 |
Why?
| | Delivery, Obstetric | 5 | 2021 | 161 | 0.760 |
Why?
| | Atrioventricular Block | 2 | 2026 | 44 | 0.720 |
Why?
| | Bradycardia | 2 | 2026 | 62 | 0.720 |
Why?
| | Sorbitol | 4 | 2014 | 13 | 0.710 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2011 | 203 | 0.710 |
Why?
| | Comorbidity | 2 | 2024 | 1659 | 0.700 |
Why?
| | Hydrocephalus | 4 | 2024 | 111 | 0.660 |
Why?
| | Umbilical Veins | 6 | 2009 | 56 | 0.660 |
Why?
| | Infant, Newborn, Diseases | 1 | 2022 | 115 | 0.640 |
Why?
| | Cerclage, Cervical | 2 | 2022 | 10 | 0.640 |
Why?
| | Pregnancy Complications | 7 | 2024 | 612 | 0.610 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2010 | 9 | 0.600 |
Why?
| | Uterine Cervical Incompetence | 1 | 2019 | 3 | 0.600 |
Why?
| | Altitude | 4 | 2013 | 473 | 0.580 |
Why?
| | Pregnancy, Animal | 4 | 2012 | 51 | 0.570 |
Why?
| | Birth Weight | 9 | 2021 | 511 | 0.550 |
Why?
| | Pre-Eclampsia | 4 | 2015 | 206 | 0.550 |
Why?
| | Placental Insufficiency | 7 | 2017 | 126 | 0.540 |
Why?
| | Humans | 98 | 2026 | 145491 | 0.540 |
Why?
| | Amniotic Fluid | 8 | 2024 | 79 | 0.530 |
Why?
| | Regional Blood Flow | 8 | 2011 | 515 | 0.490 |
Why?
| | Prenatal Diagnosis | 5 | 2024 | 196 | 0.480 |
Why?
| | Blood Flow Velocity | 7 | 2022 | 420 | 0.480 |
Why?
| | Internship and Residency | 3 | 2022 | 1265 | 0.470 |
Why?
| | Maternal-Fetal Exchange | 8 | 2021 | 170 | 0.460 |
Why?
| | Body Composition | 5 | 2022 | 689 | 0.450 |
Why?
| | Uterus | 3 | 2011 | 225 | 0.420 |
Why?
| | Adipose Tissue | 3 | 2016 | 644 | 0.420 |
Why?
| | Nitric Oxide | 7 | 2011 | 894 | 0.410 |
Why?
| | Amino Acids | 4 | 2021 | 521 | 0.400 |
Why?
| | Nitric Oxide Synthase | 3 | 2006 | 234 | 0.400 |
Why?
| | Premature Birth | 5 | 2024 | 387 | 0.400 |
Why?
| | Disease Models, Animal | 15 | 2021 | 4559 | 0.400 |
Why?
| | Fetal Therapies | 5 | 2024 | 47 | 0.390 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 174 | 0.390 |
Why?
| | Lung | 14 | 2026 | 4103 | 0.390 |
Why?
| | Puerperal Disorders | 2 | 2008 | 37 | 0.380 |
Why?
| | Laser-Doppler Flowmetry | 3 | 2005 | 31 | 0.370 |
Why?
| | Pulsatile Flow | 7 | 2011 | 59 | 0.370 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 601 | 0.360 |
Why?
| | NFATC Transcription Factors | 1 | 2012 | 94 | 0.350 |
Why?
| | Apoptosis | 5 | 2017 | 2411 | 0.340 |
Why?
| | Blood Pressure | 4 | 2017 | 1782 | 0.330 |
Why?
| | Amnion | 2 | 2026 | 31 | 0.330 |
Why?
| | Iron-Dextran Complex | 2 | 2003 | 7 | 0.330 |
Why?
| | Retrospective Studies | 19 | 2025 | 17269 | 0.320 |
Why?
| | Organ Size | 11 | 2015 | 461 | 0.320 |
Why?
| | Biometry | 2 | 2008 | 66 | 0.320 |
Why?
| | Adult | 32 | 2026 | 40707 | 0.310 |
Why?
| | Amniocentesis | 4 | 2019 | 20 | 0.310 |
Why?
| | Prospective Studies | 11 | 2026 | 8039 | 0.310 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2009 | 37 | 0.310 |
Why?
| | Caspase 3 | 1 | 2010 | 234 | 0.300 |
Why?
| | Gastroschisis | 2 | 2020 | 33 | 0.300 |
Why?
| | Hemodynamics | 8 | 2009 | 1116 | 0.300 |
Why?
| | Pregnancy Reduction, Multifetal | 2 | 2021 | 5 | 0.300 |
Why?
| | Fetal Blood | 4 | 2024 | 325 | 0.290 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2011 | 436 | 0.290 |
Why?
| | Amino Acids, Essential | 1 | 2008 | 13 | 0.290 |
Why?
| | Polycythemia | 2 | 2021 | 25 | 0.290 |
Why?
| | Twins, Monozygotic | 2 | 2021 | 134 | 0.270 |
Why?
| | Heart Rate | 2 | 2012 | 859 | 0.270 |
Why?
| | Animals | 41 | 2021 | 38141 | 0.270 |
Why?
| | Iliac Vein | 1 | 2008 | 16 | 0.270 |
Why?
| | Nutritional Status | 1 | 2010 | 352 | 0.270 |
Why?
| | Papio | 5 | 2021 | 69 | 0.270 |
Why?
| | Femoral Vein | 1 | 2008 | 38 | 0.260 |
Why?
| | Protein Kinases | 1 | 2009 | 314 | 0.260 |
Why?
| | Iliac Artery | 1 | 2008 | 60 | 0.260 |
Why?
| | Dystocia | 1 | 2007 | 12 | 0.260 |
Why?
| | Heart Rate, Fetal | 3 | 2026 | 31 | 0.260 |
Why?
| | Pregnancy Trimester, Third | 5 | 2024 | 118 | 0.250 |
Why?
| | MicroRNAs | 2 | 2024 | 689 | 0.240 |
Why?
| | Oligohydramnios | 1 | 2026 | 16 | 0.240 |
Why?
| | Polyhydramnios | 2 | 2023 | 17 | 0.240 |
Why?
| | Airway Obstruction | 2 | 2020 | 154 | 0.230 |
Why?
| | Risk Factors | 9 | 2025 | 10874 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2008 | 194 | 0.230 |
Why?
| | Transcription Factors | 2 | 2014 | 1733 | 0.230 |
Why?
| | Retroviridae | 2 | 2002 | 101 | 0.220 |
Why?
| | Umbilical Cord | 6 | 2026 | 92 | 0.220 |
Why?
| | Trophoblasts | 5 | 2015 | 218 | 0.210 |
Why?
| | Renal Insufficiency | 1 | 2026 | 172 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3897 | 0.210 |
Why?
| | Bartter Syndrome | 1 | 2023 | 7 | 0.200 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 355 | 0.200 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 344 | 0.200 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2004 | 85 | 0.200 |
Why?
| | Asphyxia | 1 | 2003 | 24 | 0.200 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 21 | 0.200 |
Why?
| | RNA, Messenger | 7 | 2012 | 2820 | 0.200 |
Why?
| | Prenatal Care | 4 | 2022 | 312 | 0.200 |
Why?
| | Fever | 6 | 2009 | 317 | 0.190 |
Why?
| | Pregnancy Proteins | 2 | 2015 | 35 | 0.190 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2024 | 117 | 0.190 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 117 | 0.190 |
Why?
| | Models, Animal | 3 | 2012 | 395 | 0.190 |
Why?
| | Osmolar Concentration | 3 | 2014 | 169 | 0.190 |
Why?
| | Transduction, Genetic | 2 | 2002 | 132 | 0.190 |
Why?
| | Infant | 9 | 2026 | 10064 | 0.190 |
Why?
| | Blood Vessels | 2 | 2000 | 167 | 0.180 |
Why?
| | Pulmonary Surfactants | 2 | 1993 | 104 | 0.180 |
Why?
| | Uterine Cervical Diseases | 1 | 2022 | 6 | 0.180 |
Why?
| | Fetal Monitoring | 1 | 2002 | 20 | 0.180 |
Why?
| | Blood Circulation | 1 | 2002 | 44 | 0.180 |
Why?
| | Cesarean Section | 4 | 2026 | 230 | 0.180 |
Why?
| | Meconium | 1 | 2001 | 9 | 0.180 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2001 | 11 | 0.180 |
Why?
| | Cervix Uteri | 1 | 2022 | 50 | 0.170 |
Why?
| | Genetic Vectors | 2 | 2002 | 335 | 0.170 |
Why?
| | Diet, Protein-Restricted | 1 | 2021 | 11 | 0.170 |
Why?
| | Rheology | 1 | 2022 | 94 | 0.170 |
Why?
| | Aspirin | 2 | 2015 | 407 | 0.170 |
Why?
| | Hot Temperature | 3 | 2014 | 411 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 389 | 0.170 |
Why?
| | Amino Acid Transport System L | 1 | 2021 | 19 | 0.170 |
Why?
| | Case-Control Studies | 6 | 2024 | 3619 | 0.170 |
Why?
| | Nasopharynx | 1 | 2001 | 73 | 0.170 |
Why?
| | Embryonic and Fetal Development | 5 | 2002 | 93 | 0.170 |
Why?
| | Emergencies | 1 | 2022 | 175 | 0.170 |
Why?
| | Amino Acid Transport System A | 1 | 2021 | 37 | 0.170 |
Why?
| | Retrognathia | 1 | 2020 | 4 | 0.170 |
Why?
| | Twins, Dizygotic | 1 | 2021 | 109 | 0.160 |
Why?
| | Biomarkers | 4 | 2024 | 4283 | 0.160 |
Why?
| | Fetal Death | 3 | 2023 | 58 | 0.160 |
Why?
| | Heart Diseases | 1 | 2004 | 342 | 0.160 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 2002 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 239 | 0.160 |
Why?
| | Bupivacaine | 1 | 2020 | 40 | 0.160 |
Why?
| | Arm | 2 | 2016 | 111 | 0.160 |
Why?
| | Micrognathism | 1 | 2020 | 19 | 0.160 |
Why?
| | Respiration | 4 | 2006 | 206 | 0.160 |
Why?
| | Myometrium | 2 | 2011 | 38 | 0.160 |
Why?
| | Ductus Arteriosus | 3 | 2018 | 72 | 0.160 |
Why?
| | Goats | 1 | 1999 | 18 | 0.150 |
Why?
| | Anesthetics, Local | 1 | 2020 | 104 | 0.150 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 1999 | 107 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 951 | 0.150 |
Why?
| | Lung Diseases | 1 | 2026 | 783 | 0.150 |
Why?
| | Anemia | 1 | 2021 | 190 | 0.150 |
Why?
| | Obstetric Surgical Procedures | 1 | 2019 | 6 | 0.150 |
Why?
| | Leg | 2 | 2016 | 244 | 0.150 |
Why?
| | Reference Values | 4 | 2008 | 797 | 0.150 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1710 | 0.150 |
Why?
| | Pregnancy Trimester, Second | 3 | 2017 | 83 | 0.150 |
Why?
| | Maternal Health | 1 | 2019 | 50 | 0.140 |
Why?
| | Tocolytic Agents | 1 | 2018 | 16 | 0.140 |
Why?
| | Indomethacin | 1 | 2018 | 76 | 0.140 |
Why?
| | Registries | 2 | 2025 | 2410 | 0.140 |
Why?
| | Time Factors | 8 | 2019 | 7171 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2020 | 188 | 0.140 |
Why?
| | Colorado | 7 | 2020 | 4572 | 0.140 |
Why?
| | Biological Transport | 3 | 2021 | 422 | 0.130 |
Why?
| | Hyaline Membrane Disease | 2 | 1997 | 20 | 0.130 |
Why?
| | Hysterotomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2021 | 335 | 0.130 |
Why?
| | Duodenal Obstruction | 1 | 2017 | 6 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 2 | 2011 | 134 | 0.130 |
Why?
| | Esophageal Atresia | 1 | 2017 | 32 | 0.120 |
Why?
| | Paralysis | 1 | 1997 | 69 | 0.120 |
Why?
| | Attitude | 1 | 2018 | 260 | 0.120 |
Why?
| | Body Mass Index | 3 | 2019 | 2425 | 0.120 |
Why?
| | Caspases | 1 | 2017 | 229 | 0.120 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1995 | 7 | 0.120 |
Why?
| | Protein S Deficiency | 1 | 1995 | 8 | 0.120 |
Why?
| | Blotting, Western | 4 | 2011 | 1162 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 909 | 0.120 |
Why?
| | Placental Circulation | 3 | 2012 | 71 | 0.120 |
Why?
| | Lateral Ventricles | 1 | 2016 | 32 | 0.120 |
Why?
| | Aldehyde Reductase | 2 | 2014 | 27 | 0.120 |
Why?
| | Hypertension | 1 | 2005 | 1273 | 0.120 |
Why?
| | Symporters | 2 | 2014 | 48 | 0.110 |
Why?
| | Mannose | 2 | 2012 | 23 | 0.110 |
Why?
| | Hypertension, Pulmonary | 3 | 2022 | 1957 | 0.110 |
Why?
| | Curriculum | 1 | 2022 | 1068 | 0.110 |
Why?
| | Choriocarcinoma | 1 | 2014 | 9 | 0.110 |
Why?
| | Coronary Circulation | 1 | 2015 | 136 | 0.110 |
Why?
| | Fetal Heart | 1 | 2015 | 56 | 0.110 |
Why?
| | Saline Solution, Hypertonic | 1 | 2014 | 43 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 324 | 0.110 |
Why?
| | Regression Analysis | 3 | 2008 | 1001 | 0.110 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2014 | 9 | 0.100 |
Why?
| | Sheep Diseases | 1 | 2014 | 9 | 0.100 |
Why?
| | Calcium | 2 | 2011 | 1190 | 0.100 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 308 | 0.100 |
Why?
| | Down-Regulation | 3 | 2021 | 616 | 0.100 |
Why?
| | Cohort Studies | 4 | 2020 | 5992 | 0.100 |
Why?
| | Bronchogenic Cyst | 1 | 2013 | 8 | 0.100 |
Why?
| | Caloric Restriction | 1 | 2015 | 126 | 0.100 |
Why?
| | Uterine Neoplasms | 1 | 2014 | 96 | 0.100 |
Why?
| | Body Weights and Measures | 1 | 2013 | 37 | 0.100 |
Why?
| | Ultrasonography | 2 | 2022 | 784 | 0.100 |
Why?
| | Coronary Vessels | 1 | 2015 | 247 | 0.100 |
Why?
| | Pilot Projects | 3 | 2020 | 1896 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 907 | 0.100 |
Why?
| | Young Adult | 6 | 2021 | 14192 | 0.100 |
Why?
| | Umbilicus | 1 | 2013 | 19 | 0.100 |
Why?
| | Rabbits | 3 | 2003 | 651 | 0.100 |
Why?
| | Fatty Alcohols | 1 | 1992 | 5 | 0.090 |
Why?
| | Phosphorylcholine | 1 | 1992 | 19 | 0.090 |
Why?
| | Femur | 3 | 2008 | 254 | 0.090 |
Why?
| | Lung Volume Measurements | 2 | 2023 | 46 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2950 | 0.090 |
Why?
| | NADP | 1 | 2012 | 53 | 0.090 |
Why?
| | Signal Transduction | 4 | 2011 | 5202 | 0.090 |
Why?
| | Calcium Signaling | 2 | 2011 | 244 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 1150 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 83 | 0.090 |
Why?
| | Estradiol | 3 | 2000 | 507 | 0.090 |
Why?
| | Animals, Newborn | 5 | 2000 | 890 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1585 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1794 | 0.080 |
Why?
| | Blood Volume | 1 | 2011 | 65 | 0.080 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2010 | 14 | 0.080 |
Why?
| | Pregnancy Trimesters | 1 | 2010 | 20 | 0.080 |
Why?
| | Keratin-18 | 1 | 2010 | 12 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2026 | 11831 | 0.080 |
Why?
| | Probability | 2 | 2001 | 310 | 0.080 |
Why?
| | Galectins | 1 | 2010 | 27 | 0.080 |
Why?
| | Chorionic Villi | 1 | 2010 | 25 | 0.080 |
Why?
| | Abdomen | 2 | 2003 | 142 | 0.080 |
Why?
| | Carbohydrate Metabolism | 1 | 2010 | 58 | 0.080 |
Why?
| | Calcium Channels | 1 | 2011 | 156 | 0.080 |
Why?
| | Carbohydrates | 1 | 2010 | 65 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2011 | 248 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2025 | 2129 | 0.080 |
Why?
| | Term Birth | 1 | 2009 | 25 | 0.080 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2009 | 16 | 0.080 |
Why?
| | TRPC Cation Channels | 1 | 2009 | 14 | 0.080 |
Why?
| | Infant, Premature | 2 | 2012 | 619 | 0.080 |
Why?
| | Oxygen | 4 | 2008 | 986 | 0.080 |
Why?
| | Diglycerides | 1 | 2009 | 61 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1242 | 0.070 |
Why?
| | High-Frequency Ventilation | 2 | 1999 | 45 | 0.070 |
Why?
| | Cordocentesis | 1 | 2008 | 1 | 0.070 |
Why?
| | Middle Cerebral Artery | 1 | 2009 | 56 | 0.070 |
Why?
| | Angiography | 1 | 2009 | 211 | 0.070 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 264 | 0.070 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 120 | 0.070 |
Why?
| | Endothelin-1 | 2 | 2008 | 181 | 0.070 |
Why?
| | Crown-Rump Length | 1 | 2008 | 2 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1392 | 0.070 |
Why?
| | Placenta Diseases | 1 | 2008 | 20 | 0.070 |
Why?
| | Blood Gas Analysis | 1 | 2008 | 81 | 0.070 |
Why?
| | Fluorocarbons | 2 | 1999 | 119 | 0.070 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 41 | 0.070 |
Why?
| | Birth Injuries | 1 | 2007 | 18 | 0.060 |
Why?
| | Polyethylene Glycols | 1 | 1992 | 652 | 0.060 |
Why?
| | Foot | 1 | 2008 | 101 | 0.060 |
Why?
| | Syndrome | 1 | 2008 | 380 | 0.060 |
Why?
| | Pulmonary Circulation | 2 | 2000 | 430 | 0.060 |
Why?
| | Shoulder | 1 | 2007 | 105 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2026 | 5426 | 0.060 |
Why?
| | Body Weight | 3 | 2006 | 970 | 0.060 |
Why?
| | Infusions, Parenteral | 1 | 2026 | 47 | 0.060 |
Why?
| | Isotonic Solutions | 1 | 2026 | 42 | 0.060 |
Why?
| | Risk | 1 | 2009 | 917 | 0.060 |
Why?
| | Sheep, Domestic | 1 | 2006 | 34 | 0.060 |
Why?
| | Glucose Transporter Type 4 | 1 | 2006 | 39 | 0.060 |
Why?
| | Polymers | 1 | 2010 | 494 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2009 | 452 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2009 | 579 | 0.060 |
Why?
| | Glucose Transporter Type 1 | 1 | 2006 | 49 | 0.060 |
Why?
| | Fetal Hypoxia | 1 | 2006 | 56 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 587 | 0.060 |
Why?
| | Vasodilation | 2 | 2000 | 521 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2007 | 113 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 3076 | 0.060 |
Why?
| | Biophysics | 1 | 2006 | 76 | 0.060 |
Why?
| | Echocardiography | 2 | 2021 | 648 | 0.060 |
Why?
| | Epinephrine | 1 | 2026 | 158 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2945 | 0.060 |
Why?
| | Receptors, Growth Factor | 2 | 2002 | 53 | 0.060 |
Why?
| | Cerebral Aqueduct | 1 | 2024 | 4 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2004 | 68 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2014 | 4127 | 0.050 |
Why?
| | Body Size | 1 | 2004 | 95 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2003 | 40 | 0.050 |
Why?
| | Heat-Shock Proteins | 2 | 2014 | 134 | 0.050 |
Why?
| | Self Report | 2 | 2018 | 871 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2003 | 550 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 848 | 0.050 |
Why?
| | Fetal Movement | 2 | 2006 | 7 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 108 | 0.050 |
Why?
| | Brain Diseases | 1 | 2004 | 153 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 2 | 2014 | 120 | 0.050 |
Why?
| | Morbidity | 1 | 2023 | 322 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2004 | 169 | 0.050 |
Why?
| | beta-Galactosidase | 1 | 2002 | 76 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 1049 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2026 | 465 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 272 | 0.040 |
Why?
| | Face | 1 | 2003 | 177 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 62 | 0.040 |
Why?
| | Apgar Score | 1 | 2001 | 21 | 0.040 |
Why?
| | Lymphokines | 1 | 2002 | 128 | 0.040 |
Why?
| | Bone and Bones | 1 | 2004 | 318 | 0.040 |
Why?
| | Perineum | 1 | 2001 | 38 | 0.040 |
Why?
| | Constriction | 2 | 2018 | 46 | 0.040 |
Why?
| | Light Coagulation | 1 | 2021 | 10 | 0.040 |
Why?
| | Suction | 1 | 2001 | 32 | 0.040 |
Why?
| | Italy | 1 | 2001 | 114 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2004 | 137 | 0.040 |
Why?
| | Laparoscopy | 2 | 1997 | 481 | 0.040 |
Why?
| | Male | 7 | 2026 | 72817 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2001 | 85 | 0.040 |
Why?
| | Algorithms | 1 | 2009 | 1855 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 372 | 0.040 |
Why?
| | Myocardium | 1 | 2006 | 932 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2023 | 426 | 0.040 |
Why?
| | Drainage | 1 | 2021 | 185 | 0.040 |
Why?
| | Gene Transfer Techniques | 1 | 2001 | 186 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 455 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2003 | 718 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 127 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2026 | 711 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 82 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 517 | 0.040 |
Why?
| | Maternal Age | 1 | 2020 | 126 | 0.040 |
Why?
| | Kidney | 2 | 2026 | 1498 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 178 | 0.040 |
Why?
| | Parietal Bone | 1 | 1999 | 9 | 0.040 |
Why?
| | Diffusion | 1 | 1999 | 124 | 0.040 |
Why?
| | Gastrostomy | 1 | 2021 | 130 | 0.040 |
Why?
| | Perinatal Death | 1 | 2019 | 26 | 0.040 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2019 | 44 | 0.040 |
Why?
| | Pulmonary Artery | 3 | 2000 | 1127 | 0.040 |
Why?
| | Arteries | 1 | 2000 | 261 | 0.040 |
Why?
| | Anthropometry | 1 | 1999 | 205 | 0.030 |
Why?
| | Linear Models | 2 | 2017 | 848 | 0.030 |
Why?
| | Cigarette Smoking | 1 | 2020 | 101 | 0.030 |
Why?
| | Insulin | 2 | 2006 | 2506 | 0.030 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 187 | 0.030 |
Why?
| | Phosphorylation | 2 | 2014 | 1707 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 975 | 0.030 |
Why?
| | Pancuronium | 1 | 1997 | 5 | 0.030 |
Why?
| | Tibia | 1 | 1999 | 176 | 0.030 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 1997 | 6 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1997 | 39 | 0.030 |
Why?
| | Intestinal Atresia | 1 | 2017 | 17 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2019 | 217 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 2093 | 0.030 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1997 | 61 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1998 | 432 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 2030 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1997 | 105 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 1997 | 147 | 0.030 |
Why?
| | Respiration, Artificial | 2 | 1999 | 712 | 0.030 |
Why?
| | Administration, Inhalation | 4 | 1999 | 571 | 0.030 |
Why?
| | Capillary Permeability | 1 | 1997 | 132 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2017 | 81 | 0.030 |
Why?
| | Twins | 1 | 2017 | 152 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 147 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 1020 | 0.030 |
Why?
| | Insufflation | 1 | 1995 | 14 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2000 | 1304 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2015 | 69 | 0.030 |
Why?
| | Transport Vesicles | 1 | 2015 | 22 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 1997 | 297 | 0.030 |
Why?
| | Placenta Growth Factor | 1 | 2015 | 26 | 0.030 |
Why?
| | Length of Stay | 1 | 2001 | 1348 | 0.030 |
Why?
| | Carbon Dioxide | 2 | 1995 | 239 | 0.030 |
Why?
| | Saimiri | 1 | 1995 | 11 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2004 | 5891 | 0.030 |
Why?
| | Uterine Prolapse | 1 | 1995 | 14 | 0.030 |
Why?
| | United States | 3 | 2018 | 16115 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1755 | 0.030 |
Why?
| | Urethral Diseases | 1 | 1995 | 16 | 0.030 |
Why?
| | Aorta | 1 | 1998 | 439 | 0.030 |
Why?
| | Neutrophils | 2 | 1999 | 1124 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 1994 | 17 | 0.030 |
Why?
| | Genetic Therapy | 1 | 1997 | 316 | 0.030 |
Why?
| | Pelvic Inflammatory Disease | 1 | 1994 | 12 | 0.030 |
Why?
| | DNA Fragmentation | 1 | 2014 | 40 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 898 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 836 | 0.020 |
Why?
| | Program Evaluation | 1 | 2018 | 945 | 0.020 |
Why?
| | Thoracotomy | 1 | 2013 | 84 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1544 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 1995 | 122 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1047 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2014 | 182 | 0.020 |
Why?
| | Injections | 1 | 1992 | 200 | 0.020 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 6070 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 75 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2012 | 144 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 1993 | 543 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2130 | 0.020 |
Why?
| | Child, Preschool | 2 | 2026 | 11837 | 0.020 |
Why?
| | Drug Combinations | 1 | 1992 | 397 | 0.020 |
Why?
| | Radiography | 1 | 1993 | 852 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 135 | 0.020 |
Why?
| | Myo-Inositol-1-Phosphate Synthase | 1 | 2010 | 3 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1997 | 700 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 171 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 202 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2060 | 0.020 |
Why?
| | Anticoagulants | 1 | 1995 | 750 | 0.020 |
Why?
| | TRPC6 Cation Channel | 1 | 2009 | 3 | 0.020 |
Why?
| | Fructose | 1 | 2010 | 132 | 0.020 |
Why?
| | Intracellular Space | 1 | 2009 | 64 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3759 | 0.020 |
Why?
| | Efficiency | 1 | 2009 | 104 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2011 | 231 | 0.020 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 2008 | 7 | 0.020 |
Why?
| | Sodium | 1 | 2009 | 198 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 2 | 1999 | 116 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 632 | 0.020 |
Why?
| | Head | 1 | 2008 | 121 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 373 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 22485 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 30 | 0.020 |
Why?
| | Heating | 1 | 2006 | 18 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 268 | 0.020 |
Why?
| | Glycogen | 1 | 2006 | 55 | 0.010 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 55 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2019 | 2962 | 0.010 |
Why?
| | Receptor, Insulin | 1 | 2006 | 93 | 0.010 |
Why?
| | Gene Expression | 1 | 2011 | 1478 | 0.010 |
Why?
| | Forecasting | 1 | 2008 | 391 | 0.010 |
Why?
| | Body Temperature | 1 | 2006 | 227 | 0.010 |
Why?
| | Liver | 2 | 2010 | 1895 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 306 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2011 | 866 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 831 | 0.010 |
Why?
| | Hospitals, University | 1 | 2004 | 176 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 380 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2006 | 339 | 0.010 |
Why?
| | Nuclease Protection Assays | 1 | 2003 | 4 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2003 | 24 | 0.010 |
Why?
| | Drinking | 1 | 2003 | 44 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2003 | 203 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 456 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 86 | 0.010 |
Why?
| | Respiratory Mechanics | 1 | 2003 | 74 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2003 | 74 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2004 | 255 | 0.010 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2002 | 25 | 0.010 |
Why?
| | Placentation | 1 | 2002 | 52 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 78 | 0.010 |
Why?
| | Galactosides | 1 | 2001 | 9 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2594 | 0.010 |
Why?
| | Lac Operon | 1 | 2001 | 44 | 0.010 |
Why?
| | Macaca | 1 | 2001 | 66 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2001 | 156 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 142 | 0.010 |
Why?
| | Stomach | 1 | 2001 | 111 | 0.010 |
Why?
| | Morphogenesis | 1 | 2002 | 172 | 0.010 |
Why?
| | Child | 2 | 2020 | 22680 | 0.010 |
Why?
| | Transgenes | 1 | 2001 | 191 | 0.010 |
Why?
| | Glucose | 1 | 2006 | 1039 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2002 | 191 | 0.010 |
Why?
| | Species Specificity | 1 | 2002 | 573 | 0.010 |
Why?
| | Ligation | 1 | 2000 | 91 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Trachea | 1 | 2001 | 258 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.010 |
Why?
| | Esophagus | 1 | 2001 | 262 | 0.010 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 149 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 153 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1995 | 3917 | 0.010 |
Why?
| | Indoles | 1 | 2001 | 508 | 0.010 |
Why?
| | Receptor, Endothelin A | 1 | 1997 | 60 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 316 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 196 | 0.010 |
Why?
| | Blood Glucose | 1 | 2006 | 2330 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 2823 | 0.010 |
Why?
| | Acidosis, Respiratory | 1 | 1995 | 3 | 0.010 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1995 | 9 | 0.010 |
Why?
| | Postoperative Period | 1 | 1997 | 351 | 0.010 |
Why?
| | Central Venous Pressure | 1 | 1995 | 17 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 174 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2002 | 1164 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 1997 | 275 | 0.010 |
Why?
| | Prolapse | 1 | 1995 | 6 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 1995 | 66 | 0.010 |
Why?
| | Vulva | 1 | 1995 | 24 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1997 | 330 | 0.010 |
Why?
| | Cardiac Output | 1 | 1995 | 179 | 0.010 |
Why?
| | Tidal Volume | 1 | 1995 | 111 | 0.010 |
Why?
| | Lymphocytosis | 1 | 1994 | 11 | 0.010 |
Why?
| | Abdomen, Acute | 1 | 1994 | 21 | 0.010 |
Why?
| | Safety | 1 | 1997 | 357 | 0.010 |
Why?
| | Pressure | 1 | 1995 | 226 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1995 | 121 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1995 | 369 | 0.010 |
Why?
| | General Surgery | 1 | 1997 | 206 | 0.010 |
Why?
| | Catheterization, Peripheral | 1 | 1995 | 121 | 0.010 |
Why?
| | Vagina | 1 | 1995 | 203 | 0.010 |
Why?
| | Oxazoles | 1 | 1971 | 48 | 0.010 |
Why?
| | Penicillins | 1 | 1971 | 62 | 0.010 |
Why?
| | Acute Disease | 1 | 1994 | 1040 | 0.010 |
Why?
| | Chronic Disease | 1 | 1997 | 1816 | 0.010 |
Why?
| | Databases, Factual | 1 | 1997 | 1500 | 0.010 |
Why?
| | Leukocytes | 1 | 1971 | 295 | 0.000 |
Why?
| | Respiratory Tract Infections | 1 | 1971 | 395 | 0.000 |
Why?
| | Mice | 1 | 2001 | 18338 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 36176 | 0.000 |
Why?
| | Dicloxacillin | 1 | 1971 | 1 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1971 | 164 | 0.000 |
Why?
| | Imidazoles | 1 | 1971 | 246 | 0.000 |
Why?
| | Administration, Oral | 1 | 1971 | 863 | 0.000 |
Why?
|
|
Galan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|